Colorectal cancer is one of the most common cancers worldwide. The majority of CRC is sporadic that occur in persons without a family history of CRC. Colorectal cancer is a multi-stage disease in which genetic and epigenetic changes accumulate gradually. Although the occurrence of these molecular changes in many cells may be accidental, the coincidental accumulation of these changes in tumor is probably due to the advantages or disadvantages caused by many of these changes. In recent years, researchers have tried to find good molecular biomarkers with different expression pattern in early and advanced stages. Long non-coding RNAs (LncRNAs), longer than 200 bp, count as appropriate markers. CRC-related lncRNAs and microRNAs are reported to be involved in diverse molecular processes such as metastasis, invasion, cell proliferation and apoptosis .Their potential role in this cancer can be examined. The purpose of this study was to evaluate the expression of the SNHG1 and miR-195 genes in CRC tumor samples compared to normal samples.

Method In this study, a total of 20 pairs of colorectal adenocarcinoma fresh tissue samples were obtained from Iran National Tumor Bank. All of the tissue specimens were frozen in liquid nitrogen after collection and then stored in -80˚C until the extraction of Total RNA.Total RNA was extracted from tissue samples, and the expression levels of SNHG1 lncRNA and miR-195 were quantified by Real-time PCR in tumor and normal tissue samples after checking the quality and quantity of RNA. Statistical analysis was done using the GraphPad Prism v6 software.

Results SNHG1 was significantly up-regulated in tumor tissues compared to their matched normal tissues. miR-195 expression was significantly down-regulated in tumor samples.
Also, SNHG1 up-regulated in tumors with higher TNM stages and larger sizes. This findings suggest a potential role for SNHG1 and miR-195.
The current study can be a basis for further experiments on the exact functions of SNHG1 as potential biomarker or therapeutic targets in cancer related pathways.